Skip to content

Building the future of targeted immune therapeutics

Our Approach
Our Team

Building the future of targeted immune therapeutics

Transforming the lives of patients with immune disease through discovery and development of targeted biotherapeutics that rebalance the immune system


Q32 Bio is comprised of an experienced and high-performing team of industry professionals including talented scientists, immunologists, and drug developers empowered to deliver on OUR mission.

Currently, Q32 Bio has two programs being evaluated in clinical trials:

Our Pipeline
Bempikibart (ADX-914)
Adaptive System Modulator

Bempikibart, Q32 Bio’s most advanced product candidate, is a fully human anti–interleukin-7 receptor alpha (IL-7Rα) antagonist monoclonal antibody (mAb) designed to re-regulate adaptive immune function by blocking signaling mediated by IL-7 and thymic stromal lymphopoietin (TSLP). Bempikibart is currently being evaluated in a double-blind, placebo-controlled Phase 2 study in patients with atopic dermatitis (AD) and an additional double-blind, placebo-controlled Phase 2 study in patients with alopecia areata (AA).

ADX-097
Innate System Modulator

ADX-097, the lead product candidate from Q32 Bio’s tissue-targeted complement inhibitor platform, is a humanized anti-C3d mAb fusion protein. ADX-097 is designed to restore complement regulation—an integral part of the innate immune system—through a novel, tissue-targeted mechanism. Q32 Bio has completed its Phase 1 clinical trial of ADX-097 in healthy volunteers and is planning to evaluate ADX-097 in an open-label Phase 2 renal basket clinical trial and a Phase 2 clinical trial in ANCA-Associated Vasculitis (AAV).